What must a manufacturer provide for an NDA?

A manufacturer must provide evidence of drug efficacy and safety for a New Drug Application (NDA) to ensure that the drug is both effective for its intended use and safe for patients. This evidence is typically presented through clinical trial data, which includes results from various phases of trials that systematically evaluate the drug's effects on health outcomes.

The requirement for efficacy and safety is foundational to the drug approval process, as it helps regulatory agencies like the FDA assess whether the benefits of the drug outweigh the risks associated with its use. Such information is critical for the protection of public health, ensuring that only those drugs that have been rigorously tested and proven to be safe and effective are available on the market.

The other options, such as providing just the drug's brand name or details of a marketing strategy, do not align with the scientific documentation and regulatory standards expected in an NDA. Similarly, clinical trial results from other drugs do not fulfill the requirement for evidence for the specific drug in question, as each drug must be evaluated on its own merits based on its direct clinical data.